Skip to Main Content

Paper Details

Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade.
Nat Med
2
2023
ICB, LS, LS-associated tumors, Lynch syndrome, Neoplasia, cancer, dMMR malignant or, dMMR tumors, malignancies, mismatch repair-deficient (dMMR) tumors, patients, pre-malignant neoplasia, premalignant, premalignant polyps, tumor, visceral tumors
Author NameAffiliation
Dana E RathkopfMemorial Sloan Kettering Cancer Center
Dana E RathkopfWeill Cornell Medical College
Michael F WalshMemorial Sloan Kettering Cancer Center
Michael F WalshWeill Cornell Medical College
Michael F WalshNiehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center
Michael F WalshMemorial Sloan Kettering Cancer Center
Chaitanya BandlamudiMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerWeill Cornell Medical College
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
  • 1 - 10

Datasets

Release 1.2